Prof. Alimonti from the Institute of Oncology Research (IOR) in Bellinzona, Switzerland and Prof. De Bono from the Institute of Cancer Research (ICR) in London, United Kingdom, just received this prestigious award for their work on targeting the host microbiota to reverse therapeutic resistance in lethal prostate cancers.
Microbiota are microorganisms living in symbiosis with the host reported to be fundamental to homeostasis; their perturbation, microbial dysbiosis, is documented in different cancer contexts and has relevance to disease progression and therapeutic response, with recent research focusing on impact on immunotherapy responsiveness. To date, little is known about gastrointestinal (GI), urinary and intratumor dysbiosis in prostate cancer (PC) and its implications, although evidence is mounting that microbiota can generate androgenic steroids. We will systematically address the role of intestinal microbiota in PC endocrine resistance, utilizing acquired data to understand more broadly the role of microbiota in prostate carcinogenesis and PC growth.
